- Home
- MCRI vs VRDN Comparison
MCRI vs VRDN Comparison
Compare MCRI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | VRDN |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MCRI | VRDN |
|---|---|---|
| Price | $117.24 | $19.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $111.50 | $35.46 |
| AVG Volume (30 Days) | 176.9K | ★ 2.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 41.41 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $395,377,000.00 | $5,706,000.00 |
| Revenue This Year | $4.85 | $13.73 |
| Revenue Next Year | $2.21 | $279.00 |
| P/E Ratio | $81.83 | ★ N/A |
| Revenue Growth | ★ 114.40 | N/A |
| 52 Week Low | $88.13 | $13.18 |
| 52 Week High | $135.93 | $34.29 |
Technical Indicators
Market Signals| Indicator | MCRI | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 55.65 |
| Support Level | $113.63 | $15.58 |
| Resistance Level | $121.15 | $20.44 |
| Average True Range (ATR) | 3.80 | 0.87 |
| MACD | -1.24 | -0.14 |
| Stochastic Oscillator | 26.33 | 45.36 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.